Search Results

Lannett Company, Inc. (OTCMKTS: LCIN) (the “Company” or “Lannett”) today announced that, together with certain of its subsidiaries (collectively with the Company, as applicable, the “Company Parties”), it has entered into a Restructuring Support Agreement (the “RSA”) with holders of more than 80% of its 7.750% senior secured notes due 2026.

Lannett Company, Inc. (LCI) (“Lannett” or “the Company”) today announced that it received a written notice from the New York Stock Exchange (“NYSE”) dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company’s common stock from the NYSE.

Lannett Company, Inc. announced that it and certain of its subsidiaries have commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the District of Delaware to effectuate the transactions contemplated by the Restructuring Support Agreement announced on May 1, 2023.

Lannett Company, Inc. announced that it and certain of its subsidiaries have successfully emerged from their Chapter 11 cases following the confirmation of its Plan of Reorganization on June 8, 2023.

Lannett Company, Inc. shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.

Lannett Company, Inc. (NYSE: LCI) today provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products.

Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m. Eastern Time on February 6, 2023.

Lannett Company, Inc. reported financial results for its fiscal 2023 second quarter ended December 31, 2022.